Eli Lilly Shares Rise After Zepbound Sleep Apnea Approval
Eli Lilly sees stock surge as Zepbound receives regulatory approval for treating sleep apnea. Discover how this impacts the healthcare market.
Topic
Healthcare
A collection of 81 issues
Breakthrough Drug Reduces Sleep Apnea Symptoms
Discover a groundbreaking drug that's five times more effective than a placebo in treating sleep apnea, with 50% of patients experiencing complete relief.
Zepbound Approved: Boosting Weight Loss and Sleep Apnea Solutions
Discover the impact of Zepbound's approval on pharmaceutical advancements in weight loss and sleep apnea treatments. Explore its significance in healthcare.
Eli Lilly's Zepbound Gains FDA Approval for Sleep Apnea
Eli Lilly's Zepbound receives FDA approval, impacting pharmaceutical and medical device markets in sleep apnea treatment.
Novo Nordisk Leads Healthcare Stocks with 9% Surge
Healthcare stocks surged as Novo Nordisk rallied 9%, bouncing back from prior session lows. Discover the latest momentum in healthcare investments.
Stoxx 600 Rises as Novo Nordisk Boosts Healthcare Stocks
Stoxx Europe 600 Index up 0.3%, led by healthcare with Novo Nordisk's recovery. Explore European markets and equity performance trends.
Eli Lilly Expands While Novo Nordisk Faces Obesity Drug Market Challenges
Eli Lilly's expansion and Novo Nordisk's struggles underscore the volatility in the obesity drug market, impacting healthcare and pharma sectors.
Anavex Shares Dip Amid Market Trends
Anavex stock sees a decline: down over 7% YTD and over 1% in 12 months. Explore the latest trends in healthcare stock performance.
Anavex Narrows Annual Loss to $43 Million
Anavex's annual financial report reveals a narrowed loss of $43 million or 52 cents per share, showcasing improved performance in the healthcare sector.
Anavex Life Sciences Reports Q4 Loss of $11.6 Million
Anavex Life Sciences Corp. posted a fiscal Q4 loss of $11.6 million, translating to 14 cents per share. Explore the impacts on the healthcare sector.